Iscador Qu as Supportive Treatment in Colorectal Cancer (Union International Cancer Control, UICC Stages II-IV)

Launched by IFAG AG · Oct 6, 2011

Keywords

ClinConnect Summary

see summary

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Confirmed diagnosis of colorectal cancer, UICC stage II-IV
• • Age between 18 (Austria: 19) and 85 years
• • No previous malign tumor
• • Surgical resection of the tumor if indicated
• • (Post-operative) conventional oncological therapy and measurements, or passive after-care ("best care")
• • Follow-up for several years feasible
• • Patient gives written consent to use the anonymized date for evaluation
• Exclusion Criteria:
• • Anal cancer
• • Other Iscador® sorts than Qu in the test group
• • Other mistletoe preparations in the test group
• • Any mistletoe preparation in the control group
• • Non-oncological immunomodulating, -stimulating or -suppressive drugs (e.g. Echinacea, interferons, Polyerga®, BCG, azathioprine). Allowed are approved tumor inhibiting immuno- or targeted therapies (e.g. bevacizumab, cetuximab) and tumor specific vaccines
• • HIV infection, Aids, organ transplantation
• • High-dose systemic glucocorticoids
• • Contraindications for Iscador® Qu (allergy against mistletoe, acute inflammatory disease or fever \> 38.5°C, active tuberculosis, hyperthyreosis with not-adjusted metabolism, primary brain or spinal tumor, brain metastases)
• • Known mistletoe intolerance
• • Patients participating in another clinical study with non-approved substances